ClinicalTrials.gg
RecruitingNCT07847918Updated Sep 29, 2026

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

A Phase 2 interventional study of Glycerol Phenylbutyrate in SLC6A1, sponsored by Scripps Translational Science Institute. Recruiting at 1 site in United States. Open to participants aged 2 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Scripps Translational Science Institute · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
2 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Planned enrollment
32nd of 43
20 · median 36
Started
2026
with 3 others
Phase 2
9 of 61
1 open now
Primary completion
2029-03
later than 14 of 16 live
Registered
61st of 61
by date

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 32nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 61st registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the feasibility of a site-less (fully remote) clinical trial using phenylbutyrate for SLC6A1-related disorders. Study participants will receive treatment with phenylbutyrate, undergo electroencephalogram (EEG) monitoring, and complete laboratory testing. Caregivers will report seizure frequency, answer questionnaires, and report side effects.

Participants will be randomly assigned to one of two groups. Randomization is stratified by age band (\<7 years vs. ≥7 years) and baseline seizure frequency (≤5 vs. >5 daily seizures). One group will begin treatment immediately; the other group will have a 6-week observation period before starting treatment. All participants will receive phenylbutyrate. Treatment lasts up to 18 weeks with the option to extend for up to 3 years. Follow-up occurs at 18 weeks. If extending treatment, additional follow-up occurs at 6 months, 1 year, and then annually.

Participation is completely voluntary. There is the risk of adverse events from the study drug, phenylbutyrate, including hospitalization from metabolic acidosis. There is the risk of loss of confidentiality of your medical and personal information collected for this study. This study does not replace emergency medical care.

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Read the detailed description

The purpose of this study is to determine whether a site-less (fully remote) clinical trial design, one conducted entirely remotely without a physical clinic site, is feasible for families affected by SLC6A1-related disorders. A secondary purpose is to explore the safety, tolerability, and preliminary effectiveness of phenylbutyrate in this population.

SLC6A1-related disorder is a rare genetic condition that causes epilepsy and intellectual disability. It is caused by variants in the SLC6A1 gene, which encodes a protein called GABA transporter 1 (GAT-1) that helps regulate the brain chemical gamma-aminobutyric acid (GABA). Phenylbutyrate is a medication that is Food and Drug Administration (FDA) -approved for a different condition (urea cycle disorders) and is being studied here for its potential antiseizure effects in SLC6A1-related disorders. Early studies have suggested that phenylbutyrate may reduce seizure frequency in some individuals with this condition, but it has not yet been studied in a controlled clinical trial. This study will help determine whether a larger, controlled trial is feasible using a site-less (fully remote) design and will provide early information about how well phenylbutyrate works and how well it is tolerated in this population.

03

Conditions studied

  • SLC6A1

Browse trials for

Keywords

  • SLC6A1
  • GAT-1
  • developmental and epileptic encephalopathy
  • DEE
  • phenylbutyrate
  • glycerol phenylbutyrate
  • 4-phenylbutyrate
  • 4-PBA
  • Ravicti
  • myoclonic atonic epilepsy
  • myoclonic-astatic epilepsy
  • Doose syndrome
  • decentralized
  • decentralized clinical trial
  • site-less
  • remote clinical trial
  • remote
  • virtual clinical trial
  • virtual
  • direct-to-patient
  • nationwide
  • digital
  • site less
04

Who can participate

Ages eligible
2 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of SLC6A1-related disorder based on a pathogenic or likely pathogenic variant in the SLC6A1 gene
  • Age 2-60 years at time of consent
  • Active clinical seizures, defined as ≥4 seizures in the 4 weeks prior to enrollment
  • Seizures persisting despite an adequate trial of ≥2 prior antiseizure medications at therapeutic doses
  • Stable antiseizure medication regimen for ≥4 weeks prior to enrollment
  • Parent, legal guardian, or legally authorized representative (LAR) able to provide and participate in digital follow-up assessments
  • Local licensed physician identified for ordering laboratory testing, EEG, and clinical evaluation as needed
  • English-speaking caregiver for consent and study communication

Exclusion criteria

Exclusion Criteria:

  • Larger 3p25 chromosomal deletion extending beyond SLC6A1 and SLC6A11 to encompass additional genes
  • Early-infantile developmental and epileptic encephalopathy (DEE) phenotype
  • Epileptic spasms within the 6 months prior to enrollment
  • Hepatic impairment ( or ALT >2× the )
  • Renal impairment ( \<60 mL/min/1.73m²)
  • Thrombocytopenia ( count \<150 × 10³/μL)
  • Inborn errors of beta-oxidation
  • Pancreatic insufficiency or intestinal malabsorption
  • Known to phenylbutyrate or any of its components
  • Participation in another interventional study within 30 days or 5 half-lives of the investigational product, whichever is longer
  • Current use of alfentanil, quinidine, cyclosporine, or probenecid due to interactions with phenylbutyrate based on modulation
  • Pregnancy or breastfeeding
  • Any condition that in the investigator's judgment would interfere with study participation or safety monitoring

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm A (Immediate Start)

    Arm A will receive immediate treatment with phenylbutyrate beginning week 0 through week 18.

    Drug: Glycerol Phenylbutyrate

  • Active comparator
    Arm B (Delayed Start)

    Arm B will have a delayed start with an observation period weeks 0-6 followed by treatment beginning at week 6 through week 18.

    Drug: Glycerol Phenylbutyrate

Interventions

  • Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy. Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA

06

What researchers measure

Primary outcomes

  1. Recruitment efficiency

    Number of participants enrolled and time from first contact to consent, averaged across the enrollment period. Target: ≥20 participants enrolled over 24 months.

    Time frame: From study opening through end of enrollment (approximately 2 years)

  2. Protocol adherence: seizure diary completion

    Proportion of weekly seizure diary entries completed at scheduled intervals across the 18-week assessment period. Target: ≥80% of scheduled entries completed.

    Time frame: Weeks 0-18

  3. Protocol adherence: Electroencephalogram (EEG) completion

    Proportion of participants completing baseline, week 6, and 18-week EEG as specified by protocol. Target: ≥80%.

    Time frame: Baseline, week 6 and week 18

  4. Protocol adherence: side effect questionnaire completion

    Proportion of scheduled side effect questionnaires completed at protocol-specified intervals from treatment initiation through week 18. Target: ≥80%.

    Time frame: From treatment initiation through week 18

  5. Protocol adherence: safety laboratory completion

    Proportion of participants completing scheduled safety laboratory testing at 6 weeks after treatment initiation. Target: ≥80%.

    Time frame: 6 weeks after treatment initiation

  6. Retention

    Proportion of enrolled participants completing the 18-week assessment period without voluntary or involuntary withdrawal. Target: ≥80%.

    Time frame: Week 18

  7. Caregiver satisfaction: overall satisfaction

    Median score on User Experience Questionnaire item Q1 assessing overall satisfaction with remote clinical trial participation. Scale 1-5 (1=very dissatisfied, 5=very satisfied). Target: median ≥4.

    Time frame: Week 18

  8. Caregiver satisfaction: acceptability

    Proportion of caregivers responding "Yes" to User Experience Questionnaire item Q2 asking whether they would recommend participating in a remote clinical trial to other families. Target: ≥80%.

    Time frame: Week 18

  9. Caregiver satisfaction: fit with daily routine

    Median score on User Experience Questionnaire item Q3 assessing whether the study fit well into the family's daily routine. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

    Time frame: Week 18

  10. Caregiver satisfaction: clarity of study procedures

    Median score on User Experience Questionnaire item Q4 assessing ease of understanding study procedures and requirements. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

    Time frame: Week 18

  11. Caregiver satisfaction: time burden

    Median score on User Experience Questionnaire item Q5 assessing ease of finding time to complete study tasks. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

    Time frame: Week 18

  12. Caregiver satisfaction: study team communication

    Median score on User Experience Questionnaire item Q6 assessing clarity and helpfulness of study team communication. Scale 1-5 (1=not at all clear/helpful, 5=extremely clear/helpful). Target: median ≥4.

    Time frame: Week 18

  13. Caregiver satisfaction: adequacy of remote safety monitoring

    Median score on User Experience Questionnaire item Q7 assessing whether the participant's safety was adequately monitored during the remote trial. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

    Time frame: Week 18

  14. Caregiver satisfaction: access to medical support

    Median score on User Experience Questionnaire item Q8 assessing ease of accessing medical support or advice when needed. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

    Time frame: Week 18

  15. Caregiver satisfaction: Research Electronic Data Capture (REDCap) usability

    Median score on User Experience Questionnaire item Q9 assessing comfort using the REDCap platform for study participation. Scale 1-5 (1=very uncomfortable, 5=very comfortable). Target: median ≥4.

    Time frame: Week 18

  16. Caregiver satisfaction: instructional video usefulness

    Median score on User Experience Questionnaire item Q10 assessing usefulness of instructional videos provided through REDCap. Scale 1-5 (1=not at all useful, 5=extremely useful). Target: median ≥4.

    Time frame: Week 18

  17. Caregiver satisfaction: optional phone call helpfulness

    Median score on User Experience Questionnaire item Q12 among participants who participated in the optional phone call at 4 weeks after treatment initiation (Q11=Yes). Scale 1-5 (1=not at all helpful, 5=extremely helpful). Proportion participating reported separately. Target: median ≥4 among participants.

    Time frame: 4 weeks after treatment initiation

  18. Caregiver experience: facilitators and barriers

    Thematic summary of free-text responses to User Experience Questionnaire items Q13 (what participants liked most) and Q14 (challenges faced). Analyzed qualitatively to identify themes relevant to remote trial design.

    Time frame: Week 18

Secondary outcomes

  1. Seizure frequency: percent change from baseline

    Percent change in average weekly seizure frequency from the baseline observation period to weeks 14-18 of treatment (stable dose period), based on caregiver-completed seizure diaries. Analyzed descriptively.

    Time frame: Baseline through week 18

  2. Seizure frequency: responder rate

    Proportion of participants achieving ≥50% reduction in average weekly seizure frequency from baseline to the stable dose period (weeks 14-18 of treatment). Analyzed descriptively.

    Time frame: Baseline through week 18

  3. Caregiver Global Impression of Change (CGIC)

    Caregiver-rated global impression of change since starting phenylbutyrate, assessed using a 7-point scale (1=very much improved, 7=very much worse). Analyzed descriptively.

    Time frame: Week 18

  4. Adaptive behavior: Vineland Adaptive Behavior Scales, Third Edition (VABS-3) composite score

    Change in VABS-3 Adaptive Behavior Composite score from baseline to week 18. Standard scores range 20-160; higher scores indicate better adaptive functioning. Analyzed descriptively.

    Time frame: Baseline and week 18

  5. Behavior: Aberrant Behavior Checklist Community Version

    Change in total score and subscale scores (Irritability/Agitation, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, Inappropriate Speech) from baseline to week 18. Total scores range 0-174; higher scores indicate more frequent or severe behavioral difficulties. Analyzed descriptively.

    Time frame: Baseline and Week 18

  6. Quality of life: QI-Disability score

    Change in Quality of Life Inventory-Disability (QI-Disability) total score from baseline to week 18. Scores range 0-100; higher scores indicate better quality of life. Analyzed descriptively.

    Time frame: Baseline and week 18

  7. Medication Burden

    Change in the number of concomitant antiseizure medications (not counting glycerol phenylbutyrate) from baseline to week 18, captured via weekly seizure diary. Analyzed descriptively.

    Time frame: Baseline and Week 18

  8. Safety and tolerability: adverse events

    Frequency and severity of adverse events, serious adverse events, dose interruptions, and discontinuations throughout the study period. Summarized descriptively by event type, severity, causality, and outcome.

    Time frame: From treatment initiation through week 18

  9. Safety and tolerability: laboratory values

    Proportion of 6 week post-treatment initiation safety laboratory values that are outside pre-specified thresholds reported descriptively, including phenylacetate level \> 500 µg/mL, phenylacetic acid-to-phenylacetylglutamine (PAA-to-PAGN) ratio \> 1.5, bicarbonate level \< 17 mEq/L, anion gap \> 12 mEq/L, urine pH \< 5.5, the combination of low carnitine (total carnitine level \< 30 µmol/L OR free carnitine level \< 20 µmol/L) PLUS an elevated esterified-to-free carnitine ratio \> 0.4, and ALT or AST (exceeds 3× the upper limit of normal with symptoms, or exceeds 5× the upper limit of normal without symptoms). Each parameter is reported separately as the proportion of participants with values outside pre-specified thresholds.

    Time frame: 6 weeks after treatment initiation

  10. EEG: Delta spectral power

    Change in delta-frequency (2.5-4 Hz) EEG spectral power from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively as an exploratory biomarker of treatment response.

    Time frame: Baseline and Week 18

  11. EEG: Delta-frequency autocorrelation

    Change in EEG autocorrelation at lags corresponding to 2.5-4 Hz from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

    Time frame: Baseline and Week 18

  12. EEG: Spectral entropy

    Change in broadband (0-30 Hz) EEG spectral entropy from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

    Time frame: Baseline and Week 18

  13. EEG: Combination of three measures

    Proportion of 1-second EEG segments meeting all three pre-specified thresholds simultaneously (delta power \>105,000 μV², autocorrelation \>0.410, spectral entropy ≤3.16) in ≥3 channels, compared from baseline to week 18. Analyzed descriptively as an exploratory biomarker outcome.

    Time frame: Baseline and Week 18

  14. Concurrent randomized seizure comparison

    Proportion of participants achieving ≥50% seizure reduction in Arm A (on treatment) versus Arm B (observation period) at week 6, reported as absolute risk difference, relative risk reduction, and number needed to treat, with 95% confidence intervals. Quantitative EEG measures (delta-frequency spectral power, autocorrelation at 2.5-4 Hz lags, and broadband spectral entropy) will be compared between arms at week 6 as an exploratory biomarker. Analyzed descriptively.

    Time frame: Week 6

  15. Arm A within-person early vs. stable dose seizure comparison

    Mean weekly seizure frequency during early treatment (weeks 0-2) compared to the stable dose period (weeks 14-18) in Arm A participants. Analyzed descriptively.

    Time frame: Weeks 0-2 and weeks 14-18

  16. Arm B within-person seizure change

    Seizure frequency trajectory in Arm B, estimated using a segmented regression model assessing whether the pre-treatment slope is flat and characterizing the post-treatment slope through the stable dose period (weeks 12-18). Analyzed descriptively.

    Time frame: Weeks 0-6 and weeks 12-18 of treatment

  17. Trajectory replication across arms

    Comparison of post-treatment slopes from the segmented regression model in Arm A and Arm B, offset by 6 weeks, assessing whether the two arms show comparable seizure frequency trajectories following treatment initiation. Analyzed descriptively.

    Time frame: Weeks 0-18

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Sep 29, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2029
CompletionEst.
Oct 2032
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847918
Lead sponsor
Scripps Translational Science Institute
Responsible party
Kristen Barbour (Associate Physician, Scripps Translational Science Institute) — Principal investigator
First posted
Sep 29, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Oct 2032 (estimated)
Last update
Sep 29, 2026

Study contacts

Kristen Barbour, MD
Contact
kbarbour@scripps.edu
619-613-0693
Kristen Barbour, MD
principal investigator · This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycerol phenylbutyrate

Start the discussion